I'm hearing whispers ,, we may not be about to have a CR ,, CHM may well be a Buy/out target ..and the buyer doesn't require CHM to have any cash or staff in the transaction..
. One patient achieved a complete response which has been sustained for over 48 months and is alive today. The Phase 1B study (NCT05400122) is intended to build upon the clinical responses seen in the initial CHM CORE-NK Phase 1A clinical trial by adding vactosertib, an oral TGF-β receptor inhibitor that can potentially disrupt the TGF-β signaling pathway
CHM Price at posting:
1.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)